[1] Siegel RL, Miller KD, Jemal A. Cancer statistics 2020 [J]. CA Cancer J Clin, 2020, 70(1): 7-30.
[2] Huang KK, Liu YZh, Chen YM, et al. Inhibitory effect of oridonin on proliferation and migration of human esophageal squamous cancer cell lines KYSE-150 and KYSE-450 [J]. Acta Anatomica Sinica, 2019, 50(5): 601-609. (in Chinese)
黄坷坷,刘玉珍,陈彦民,等. 冬凌草甲素对人食管鳞癌细胞系 KYSE-150 和KYSE-450 增殖及迁移的影响 [J]. 解剖学报, 2019, 50(5): 601-609.
[3] Lagergren J, Lagergren P. Recent Developments in esophageal adenocarcinoma [J]. CA Cancer J Clin, 2013, 63(4): 232-248.
[4] Maret-Ouda J, ElSerag HB, Lagergren J. Opportunities for preventing esophageal adenocarcinoma [J]. Cancer Prev Res (Phila), 2016, 9(11): 828-834.
[5] Wang J, Li N, Wang XF, et al. Esophageal adenocarcinoma: the clinicopathologic features, patterns of lymph node metastasis and its influencing factors [J]. Chinese Journal of Oncology, 2016, 38(7): 515-520. (in Chinese)
王军, 李娜, 王雪锋,等. 食管腺癌临床病理特征及其淋巴结转移的影响因素[J].中华肿瘤杂志, 2016, 38(7): 515-520.
[6] Donato R, Sorci G, Giambanco Ⅰ. S100A6 protein: functional roles [J]. Cell Mol Life Sci, 2017, 74(15): 2749-2760.
[7] Le?niak W, Wilanowski T, Filipek A. S100A6-focus on recent developments [J]. Biol Chem, 2017, 398(10):1087-1094.
[8] Kuberappa PH, Bagalad BS, Ananthaneni A, et al. Certainty of S100 from physiology to pathology[J]. J Clin Diagn Res, 2016, 10(6):ZE10-15.
[9] Heizmann CW, Fritz G, Sch?fer B W. S100 proteins: structure, functions and pathology [J]. Front Biosci, 2002, 7:d1356-1368.
[10] Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer [J]. Nat Rev Cancer, 2015, 15(2): 96-109.
[11] Marenholz I, Heizmann C W, FritzG. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature) [J]. Biochem Biophys Res Commun, 2004, 322(4): 1111-1122.
[12] Calabretta B, Kaczmarek L, Mars W, et al. Cell-cycle-specific genes differentially expressed in human leukemias [J]. Proc Natl Acad Sci USA, 1985, 82(13): 4463-4467.
[13] He XG, Xu XL, Khan AQ, et al. High expression of S100A6 predicts unfavorable prognosis of lung squamous cell cancer [J]. Med Sci Monit, 2017, 23: 5011-5017.
[14] Zheng SS, Shen HJ, Jia QG, et al. S100A6 promotes proliferation of intrahepatic cholangiocarcinoma cells via the activation of the p38/MAPK pathway [J]. Future Oncol, 2017, 13(23): 2053-2063.
[15] Li ZQ, Tang M, Ling B, et al. Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma [J]. J Mol Med (Berl), 2014, 92(3): 291-303.
[16] Huang HL, Wu BY, Zhu XD, et al. Expression of S100A6 in primary and metastatic human gastric cancer[J]. Chinese Journal of Oncology, 2008, 30(7): 506-510. (in Chinese)
黄海力, 吴本俨, 朱旭东, 等. 胃癌及其转移灶中S100A6基因的表达[J]. 中华肿瘤杂志, 2008, 30(7): 506-510.
[17] Chen X, Liu XJ, Lang HB, et al. S100 calcium-binding protein A6 promotes epithelial-mesenchymal transition through β-catenin in pancreatic cancer cell line [J]. PLoS One, 2015 10(3): e0121319.
[18] Li YS, Wagner E R, Yan ZJ, et al. The calcium-binding protein S100A6 accelerates human osteosarcoma growth by promoting cell proliferation and inhibiting osteogenic differentiation [J]. Cell Physiol Biochem, 2015, 37(6): 2375-2392.
[19] Ning XX, Sun SR, Zhang K, et al. S100A6 protein negatively regulates CacyBP/SIP-mediated inhibition of gastric cancer cell proliferation and tumorigenesis [J]. PLoS One, 2012, 7(1): e30185.
[20] Li P, Lv XD, Zhang ZQ, et al. S100A6/miR193a regulates the proliferation, invasion, migration and angiogenesis of lung cancer cells through the P53 acetylation [J]. Am J Transl Res, 2019, 11(8): 4634-4649.
[21] Li AF, Gu Y, Li XR, et al. S100A6 promotes the proliferation and migration of cervical cancer cells via the PI3K/Akt signaling pathway [J]. Oncol Lett, 2018, 15(4): 5685-5693.
[22] Idriss MH, Elston DM. S100A6 expression in cutaneous smooth muscle neoplasms [J]. APMIS, 2015, 123(10): 832-836.
[23] Yang X, Wei KJ, Zhang L, et al. Decreased expression of S100A6 in oral squamous cell carcinoma [J]. Oncol Rep, 2010, 24(2): 479-488.
|